Deal watch: Neurokinin 3 receptor antagonist revival heats up with Astellas acquisition
Nature Reviews Drug Discovery 16, 377 (2017).
doi:10.1038/nrd.2017.102
Author: Megan Cully
Japan's Astellas Pharma has announced that it will acquire the Belgian biotech Ogeda for up to [euro]800 million, including milestone payments (Fig. 1). Ogeda's sole clinical asset, fezolinetant, is a small-molecule inhibitor of the neurokinin 3 receptor (NK3R), for which the company reported
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Megan Cully Tags: News and Analysis Source Type: research
More News: Biotechnology | Brain | Drugs & Pharmacology | Mergers and Aquisitions | Neurology | Pharmaceuticals